)
)
Edge16 Oct 2026
Winner, Winner: The Chicken McNugget Story
How a 1940s breeding contest, a Cornell food scientist, and a hedge by Ray Dalio helped McDonald's turn the Chicken McNugget into a fast-food icon.
MeiraGTx
MeiraGTx (MGTX) investor relations material
MeiraGTx Q3 2026 earnings summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.Q3 2026 earnings summary12 Nov, 2026
Executive summary
9M net income was $63.1M, primarily from non-recurring collaboration and license transactions; Q3 net loss was $51.3M, with no product sales generated.
Cash, cash equivalents and restricted cash totaled $186.8M at Sept. 30, 2026; expected Hologen funding and reimbursements are projected to support operations into H2 2028.
Financial highlights
Q3 revenue was $4.8M vs. $0.4M YoY; operating expenses were $54.7M vs. $46.5M, and operating loss was $49.9M vs. $46.1M.
9M revenue was $326.5M vs. $6.0M, including $204.6M related-party license revenue and $108.4M related-party service revenue; operating income was $153.7M vs. a $132.4M loss.
9M net income was $63.1M vs. a $129.3M net loss, reflecting non-recurring transactions including Hologen collaboration revenue.
Q3 net loss was $51.3M, or $0.53 per basic and diluted share, vs. $50.5M and $0.62 per share YoY; R&D rose to $39.3M from $32.5M while G&A fell to $12.0M from $13.6M.
Outlook and guidance
Bota-vec MAA dossier is complete, with EMA submission intended for Dec. 2026 subject to confirmation; full FDA BLA submission is expected in Q1 2027, with preparations for a potential late-2027 launch.
AQUAx2 completed enrollment in Q2 2026; pivotal 12-month data are expected mid-2027 and could support a BLA by year-end 2027 and U.S. approval in 2028 if positive.
Reogen plans to initiate a Phase 3 AAV-GAD study in Q1 2027; a SAD/MAD study of the riboswitch platform’s lead small molecule is expected to begin in Dec. 2026.
IND-enabling priorities include Ribo-Leptin and a riboswitch neuropathic-pain program; first-in-human combination studies are planned for 2027.
Significant operating losses and R&D and G&A costs are expected to continue; additional capital may be needed and may not be available on acceptable terms.
Partial view of Summaries dataset, powered by Quartr API
AI can get things wrong. Verify important information.Research faster. Power your platform.
Latest events from MeiraGTx
- Late-stage pipeline, transformative gene therapies, and strong partnerships drive near-term approvals.MGTX
Corporate presentation - Q2 2026 net income of $160.7M on $321.4M revenue, fueled by licensing, acquisitions, and clinical progress.MGTXQ2 2026
- Directors and auditor were elected and ratified, with no shareholder questions submitted.MGTXAGM 2026
- Late-stage gene therapies advance with pivotal xerostomia data, XLRP filings, and major partnerships.MGTXJefferies Global Healthcare Conference 2026
- Late-stage pipeline and riboswitch platform drive transformative therapies for major unmet needs.MGTXCorporate presentation
- Regained RPGR rights and late-stage pipeline progress position for near-term commercialization.MGTXBank of America Global Healthcare Conference 2026
- Q1 2026 net loss rose to $46.3M; FDA breakthrough, bota-vec deal, and $100M raise drive pipeline.MGTXQ1 2026
- Director elections, auditor ratification, and robust governance highlight this year's proxy.MGTXProxy filing
- Gene therapy restored vision and broad function in all 11 AIPL1-LCA children, with no safety issues.MGTXStudy Update
Next MeiraGTx earnings date
Q4 202625 Mar, 2027
MeiraGTx
Next MeiraGTx earnings date
Q4 202625 Mar, 2027
AI chat
Ask anything. Verify everything.
Ask across every event and document from public companies. Each answer links back to the exact line in the transcript, slide or filing it came from.Learn moreFind what matters
AI across all first-party IR material. Live calls, transcripts, slides, filings.)
Trust every finding
50m+ first-party documents. Every output traceable to its source.Find what matters
AI across all first-party IR material. Live calls, transcripts, slides, filings.Trust every finding
50m+ first-party documents. Every output traceable to its source.Automations
Zero in on what matters
Define the prompt once. It runs the moment a company publishes or on a schedule you set. Outputs map to the exact signals you choose.Learn more)
Event-triggered research
Runs when a company publishes new material. Trigger on the first published document for the earliest possible run, or wait for a specific one.)
Scheduled research
Runs on a recurring cadence you set. Daily, weekly, monthly, or quarterly, for aggregate reads across a period rather than a single event.Event-triggered research
Runs when a company publishes new material. Trigger on the first published document for the earliest possible run, or wait for a specific one.Scheduled research
Runs on a recurring cadence you set. Daily, weekly, monthly, or quarterly, for aggregate reads across a period rather than a single event.Live audio & transcripts
Be first
Join any earnings call live in one click, with no manual registration. Follow the transcript as it happens and jump straight to the moments that matter.Learn more)
Live earnings calls
Join any call in one click. The audio keeps playing while you work elsewhere in Quartr.)
Live transcripts
Speaker-by-speaker, in real time. Searchable across every live and historical call.Live earnings calls
Join any call in one click. The audio keeps playing while you work elsewhere in Quartr.Live transcripts
Speaker-by-speaker, in real time. Searchable across every live and historical call.Quartr MCP connects your AI environment to 17K+ public companies
Pull live transcripts, filings, and slides into Claude or Codex via MCP. Combine Quartr's global IR data with any other dataset. Run agentic research and monitoring.
Included with Quartr Pro at no extra cost.Learn more
Quartr's AI stands out because it only pulls clean, first-party data from public companies. In investing, that's everything.
Jamie Ross
Investment Manager, GAM Investments
GAM
GAM
Research that used to take hours now takes seconds with Quartr Pro. Tracking shifts in tone or extracting tables, it's as simple as typing a query.
Tom O'Hara
Investment Director
Ciena
Ciena
Before Quartr we spent hours manually compiling insights through the peer earnings cycle. Now, these tasks are done faster, with greater precision.
Gregg Lampf
VP of Investor Relations
Protean
Protean
Being able to ask specific questions across years of transcripts and reports and instantly get verified answers is a game-changer.
Pontus Dackmo
CEO & Investment Manager
)
)
Frequently asked questions
MeiraGTx Holdings plc is a clinical-stage gene therapy company dedicated to developing potentially curative treatments for patients suffering from serious diseases. The company's research and development efforts are currently concentrated on six clinical programs, which include treatments for four types of ocular diseases, a salivary gland condition, and Parkinson’s disease. MeiraGTx's approach is particularly focused on areas with significant unmet medical needs, such as diseases of the eye, salivary gland, and central nervous system. The company is headquartered in New York and London, and its shares are listed on the Nasdaq.